comprehensive -WSS

comprehensive

author：fashion 2025-09-05 07:03:00 - browse：5

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Former medical device CEO who sold dummy, plastic parts convicted of fraud

Wikipedia

WSS

Novo Nordisk obesity pill bests Wegovy in early trial

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

The Readout: Amylyx, Alumis, and Lundbeck drug updates

CDC marks new Covid

Studies point to risks of excluding people with obesity from drug trials

The EU Joint Clinical Assessment needs to live up to its promise

explore

comprehensive

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

First Opinion Podcast: Long Covid needs a new approach

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

HHS leader on health, climate change and biopharma emissions

Sports medicine is finally prioritizing gender equality

Lawmakers consider Medicare pay reforms for doctors

Hepatitis C has a cure — but many Americans still lack access to it

CEOs share strategies for surviving biotech slump

focus

Medicare reduced heart disease by changing how it pays doctors

The Readout: Amylyx, Alumis, and Lundbeck drug updates

First Opinion Podcast: Long Covid needs a new approach

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

CDC marks new Covid

Lawmakers consider Medicare pay reforms for doctors

Wikipedia

focus

leisure time

focus